Market revenue in 2023 | USD 54,097.3 million |
Market revenue in 2030 | USD 172,089.8 million |
Growth rate | 18% (CAGR from 2023 to 2030) |
Largest segment | Metabolic disorders |
Fastest growing segment | Metabolic disorders |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Cancer, Metabolic disorders, Cardiovascular disorders, Respiratory disorders, Gastrointestinal disorders, Infectious disease, Pain, Dermatological disorders, Neurological disorders, Renal disorders |
Key market players worldwide | Eli Lilly and Co, Pfizer Inc, Amgen Inc, Takeda Pharmaceutical Co Ltd, AstraZeneca PLC, Teva Pharmaceutical Industries Ltd, Sanofi SA, Roche Holding AG, Novartis AG ADR, Novo Nordisk A/S ADR, GlaxoSmithKline, Ironwood Pharmaceuticals Inc Class A, Ipsen SA, Radius Health |
Metabolic disorders was the largest segment with a revenue share of 59.46% in 2023. Horizon Databook has segmented the North America peptide therapeutics market based on cancer, metabolic disorders, cardiovascular disorders, respiratory disorders, gastrointestinal disorders, infectious disease, pain, dermatological disorders, neurological disorders, renal disorders covering the revenue growth of each sub-segment from 2018 to 2030.
North America leads the global peptide therapeutics market in terms of revenue generation, owing to the launch of effective products along with technologically advanced production facilities across the region. In addition, the increasing prevalence of diseases, such as cancer, cardiovascular disorders, respiratory diseases, infectious diseases, metabolic disorders, and others, is expected to drive market growth.
A large population is prone to major target diseases, which increases the need to develop effective therapeutics to curb their prevalence and enable effective management. Key players operating in the market are constantly focusing on product launches, collaborations, and partnerships to meet the rising demand among the population.
Both companies have been long-term partners of PeptiDream. Furthermore, the market in the region is anticipated to grow due to rising investments in the R&D of novel drugs and technological advancements pertaining to the development of effective therapeutics.
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account